GeneBio Systems
MAP2K2 Polyclonal Antibody
MAP2K2 Polyclonal Antibody
SKU:E-AB-12553
Couldn't load pickup availability
Size::120μL
Storage:Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.
Shipping:The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.
Exp date:12 months
Category ID_II:Primary Antibodies
Category ID_III:Polyclonal Antibodies
Abbreviation:MAP2K2
Target Synonym:Cardiofaciocutaneous syndrome;CFC syndrome;CFC4;Dual specificity mitogen activated protein kinase kinase 2;Dual specificity mitogen-activated protein kinase kinase 2;ERK activator kinase 2;FLJ26075;MAP kinase kinase 2;map2k2;MAPK / ERK kinase 2;MAPK/ERK kinase 2;MAPKK 2;MAPKK2;MEK 2;MEK2;Microtubule associated protein kinase kinase 2;Mitogen activated protein kinase kinase 2;Mitogen activated protein kinase kinase 2 p45;MKK 2;MKK2;MP2K2;OTTHUMP00000165826;OTTHUMP00000165827;PRKMK 2;PRKMK2
Research Areas:Cancer;Signal Transduction
Conjugation:Unconjugated
Host:Rabbit
Species reactivity:Human;Mouse;Rat
Application:WB;IHC
Isotype:IgG
Clonality:Polyclonal
Clone NO.:
UNIProt ID:P36507
Accession:
Background:The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.
Concentration:1 mg/mL
Immunogen:Synthetic peptide of human MAP2K2
Buffer:PBS with 0.05% sodium azide and 50% glycerol, PH7.4
Purification method:Affinity purification
Dilution:WB 1:1000-1:5000;IHC 1:100-1:300
Calculated MW:44kDa
ObservedMW:
